These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 35822553

  • 21. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR.
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ.
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [Abstract] [Full Text] [Related]

  • 24. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Kärkkäinen P.
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [Abstract] [Full Text] [Related]

  • 25. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
    de Vries EM, Wang J, Leeflang MM, Boonstra K, Weersma RK, Beuers UH, Geskus RB, Ponsioen CY.
    Liver Int; 2016 Dec; 36(12):1867-1875. PubMed ID: 26945698
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
    Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z.
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
    [Abstract] [Full Text] [Related]

  • 30. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
    de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, Drenth J, van Erpecum K, van Nieuwkerk K, van der Heide F, Mostafavi N, Helder J, Ponsioen C, Oude Elferink R, van Buuren H, Beuers U, Netherlands Association for the Study of the Liver-Cholestasis Working Group.
    Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
    [Abstract] [Full Text] [Related]

  • 31. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
    Ahn DW.
    Korean J Gastroenterol; 2020 May 25; 75(5):246-256. PubMed ID: 32448856
    [Abstract] [Full Text] [Related]

  • 32. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
    Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD.
    Am J Gastroenterol; 2001 May 25; 96(5):1558-62. PubMed ID: 11374699
    [Abstract] [Full Text] [Related]

  • 33. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW.
    Gastroenterology; 2001 Oct 25; 121(4):900-7. PubMed ID: 11606503
    [Abstract] [Full Text] [Related]

  • 34. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
    Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD.
    Aliment Pharmacol Ther; 2011 Nov 25; 34(10):1185-92. PubMed ID: 21957881
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, Milkiewicz P.
    Hepatology; 2014 Sep 25; 60(3):931-40. PubMed ID: 24519384
    [Abstract] [Full Text] [Related]

  • 37. Ursodeoxycholic acid for primary sclerosing cholangitis.
    Chazouillères O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet JC.
    J Hepatol; 1990 Jul 25; 11(1):120-3. PubMed ID: 1975818
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, Wu X, Zhang W, Ma H, You H, Jia J.
    Rev Esp Enferm Dig; 2018 Sep 25; 110(9):557-563. PubMed ID: 29739227
    [Abstract] [Full Text] [Related]

  • 39. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
    Reig A, Álvarez-Navascués C, Vergara M, Gómez-Domínguez E, Gallego-Moya A, Pérez-Medrano IM, Fábrega E, Hernández-Guerra M, Berenguer M, Estevez P, Arencibia A, Morillas RM, Horta D, Albillos A, Casado M, De la Cruz G, Fernandez-Bonilla E, Molina E, Hijona L, Diago M, Fernández-Rodriguez CM, González-Santiago JM, Sala M, Gómez-Camarero J, Romero-Gomez M, Suárez F, Vargas V, Ferre-Aracil C, Andrade RJ, Chahri N, Parés A.
    Am J Gastroenterol; 2021 Nov 01; 116(11):2250-2257. PubMed ID: 34158466
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.